Viatris (VTRS) Jumps 10% on Reaffirmed Growth Targets
Earlier this month, Viatris Inc.
Viatris Inc (VTRS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deerfield Management James E. Flynn | 24,099,083 | $238,580,922 | +1% | 3.64% |
| 2. | Rubric Capital Management David Rosen | 15,385,000 | $152,311,500 | +29% | 1.72% |
| 3. | Citadel Investment Group Ken Griffin | 10,466,287 | $103,616,241 | +41% | 0.02% |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 8,852,419 | $87,638,948 | +18% | 0.06% |
| 5. | Glenview Capital Larry Robbins | 8,247,584 | $81,651,082 | 1.82% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.99 | 22,000 | $219,740.40 | 314,807 | 2025-08-12 | Filing | |
| $8.94 | 60,000 | $536,262.00 | 292,807 | 2025-05-12 | Filing | |
| $9.01 | 19 | $171.13 | 94,960 | 2023-10-26 | Filing | |
| $10.42 | 239 | $2,488.12 | 94,190 | 2022-03-16 | Filing | |
| $10.08 | 1,150 | $11,590.85 | 93,951 | 2022-03-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.25 | 7,032 | $72,044.95 | 35,299 | 2025-09-11 | Filing | |
| $12.88 | 26,925 | $346,686.30 | 126,901 | 2024-11-11 | Filing | |
| $11.66 | 139,681 | $1,628,163.64 | 505,838 | 2024-09-12 | Filing | |
| $11.71 | 60,319 | $706,552.64 | 0 | 2024-09-12 | Filing | |
| $12.00 | 50,000 | $600,000.00 | 60,319 | 2024-08-30 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 140,273,202 | $1,388,704,701 | 0.02% | |
| 2. | 81,959,740 | $811,401,424 | 0.01% | |
| 3. | 69,345,645 | $686,521,885 | 3.58% | |
| 4. | 55,707,362 | $551,502,884 | 0.02% | |
| 5. | 37,370,338 | $369,940,165 | 0.08% |
News See All
Viatris Inc. (NASDAQ:VTRS) Q3 2025 Earnings Call Transcript
Operator: Good morning, and welcome to the Viatris Q3 2025 Earnings Call. [Operator Instructions] Please note, this event is being recorded.
Truist Initiates Viatris (VTRS) Coverage with Buy Rating, $15 PT
Viatris Inc. (NASDAQ:VTRS) is one of the best large cap stocks to buy under $20. On October 15, Truist’s Les Sulewski initiated coverage of Viatris with a Buy rating and $15 price target.
10 Best Large Cap Stocks to Buy Under $20
Earlier on August 29, Bob Keiser, Aspire Strategist Portfolios co-chief investment officer and senior market strategist, joined CNBC's 'Closing Bell Overtime' to suggest that earnings growth continues...
13 Best Growth Stocks Under $25 to Buy Right Now
Recently, there have been concerns around the surge of fraudulent loans and private credit quality issues in the US.
Viatris Inc. (VTRS) Gains FDA Approval for First Generic Iron Sucrose Injection
Viatris Inc. (NASDAQ:VTRS), formed from the 2020 merger of Mylan and Pfizer’s Upjohn division, delivers essential generic and specialty medicines to patients in over 165 countries.
10 Best Pharma Stocks to Buy According to Billionaires
Recently, President Trump wrote letters to 17 major pharmaceutical firms outlining the actions they should take to bring the prices of prescription pharmaceuticals in the United States down to "most favored...
12 Cheap Healthcare Stocks to Buy Now
Mizuho health care sector strategist Jared Holz made an appearance on CNBC's "The Exchange" on July 21 to discuss the challenges facing the healthcare industry and whether there are any opportunities ...
Viatris, Inc. (VTRS) Achieves Key Clinical Milestones in Ophthalmology, Pain, Women’s Health
Viatris, Inc. (NASDAQ:VTRS) reported strong Q2 2025 results, generating approximately $79 million in revenue from new products while reaffirming its full-year financial guidance.